Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vicarious Surgical ( (RBOT) ) has provided an announcement.
On September 25, 2025, Vicarious Surgical announced the appointment of Joseph Doherty as Chairman of the Board. Doherty, who joined the board in June 2025, brings extensive experience from leadership roles in the healthcare and medical device industries, including positions at Scapa Healthcare and Olympus Surgical Technologies America. His appointment is seen as pivotal for Vicarious Surgical as it aims to set new standards in robotic surgery and enhance patient outcomes, aligning with the company’s mission to transform surgical robotics and drive value for patients and shareholders.
The most recent analyst rating on (RBOT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Vicarious Surgical stock, see the RBOT Stock Forecast page.
Spark’s Take on RBOT Stock
According to Spark, TipRanks’ AI Analyst, RBOT is a Underperform.
Vicarious Surgical’s stock score reflects significant financial challenges as a pre-revenue company with high cash burn, offset by a moderately stable balance sheet. Technical analysis indicates bearish sentiment, compounded by valuation challenges due to negative earnings. While the earnings call showed strategic advancements, supply chain delays and NYSE compliance issues pose risks. Successful clinical trials and improved cash management will be critical for future performance.
To see Spark’s full report on RBOT stock, click here.
More about Vicarious Surgical
Vicarious Surgical, founded in 2014 and headquartered in Waltham, Massachusetts, is a next-generation surgical robotics company. It focuses on developing disruptive technology to enhance the efficiency of surgical procedures, improve patient outcomes, and reduce healthcare costs. The company utilizes proprietary human-like surgical robots for minimally invasive surgeries and is backed by notable investors including Bill Gates and Khosla Ventures.
Average Trading Volume: 34,460
Technical Sentiment Signal: Sell
Current Market Cap: $35.36M
For a thorough assessment of RBOT stock, go to TipRanks’ Stock Analysis page.